Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Harbeck

Showing results (91-100 of 585) with videos related to

Pageof 59
Sort By:
Future Oncology (London, England)|October 27, 2009
DNA methylation as a biomarker in breast cancerJohn Wm Martens, Astrid L Margossian, Manfred Schmitt, et al.
Breast Cancer Research and Treatment|February 9, 2012
Health-related quality of life in male breast cancer patientsChristoph Kowalski, Petra Steffen, Nicole Ernstmann, et al.
Breast Care (Basel, Switzerland)|July 23, 2011
Facilitating Early Integration of Palliative Care into Breast Cancer Therapy. Promoting Disease-Specific GuidelinesJan Gaertner, Rachel Wuerstlein, Christoph Ostgathe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
Detection and clinical implications of early systemic tumor cell dissemination in breast cancerKlaus Pantel, Volkmar Müller, Margherita Auer, et al.
Breast Cancer Research : BCR|February 14, 2015
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studiesMichael J Duffy, Patricia M McGowan, Nadia Harbeck, et al.
Anti-Cancer Drugs|December 13, 2006
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrierHans-Joachim Stemmler, Manfred Schmitt, Amina Willems, et al.
Cancer|May 10, 2022
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancerNadia Harbeck, Harold J Burstein, Sara A Hurvitz, et al.
Cancer Nursing|September 28, 2011
Associations between hospital and patient characteristics and breast cancer patients' satisfaction with nursing staffChristoph Kowalski, Sophie E Diener, Petra Steffen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 20, 2004
Biomolecular features of clinical relevance in breast cancerMaria Grazia Daidone, Angelo Paradiso, Massimo Gion, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Use of the Gene Expression Test Prosigna<sup>®</sup> in Premenopausal Patients with HR+, HER2- Early Breast Cancer: Correlation of the Results with the Proliferation Marker Ki-67Cordula Ziegler, Karl Sotlar, Daniel Maria Hofmann, et al.
Pageof 59

Showing results (91-100 of 585) with videos related to

Sort By:
Pageof 59
Future Oncology (London, England)|October 27, 2009
DNA methylation as a biomarker in breast cancerJohn Wm Martens, Astrid L Margossian, Manfred Schmitt, et al.
Breast Cancer Research and Treatment|February 9, 2012
Health-related quality of life in male breast cancer patientsChristoph Kowalski, Petra Steffen, Nicole Ernstmann, et al.
Breast Care (Basel, Switzerland)|July 23, 2011
Facilitating Early Integration of Palliative Care into Breast Cancer Therapy. Promoting Disease-Specific GuidelinesJan Gaertner, Rachel Wuerstlein, Christoph Ostgathe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
Detection and clinical implications of early systemic tumor cell dissemination in breast cancerKlaus Pantel, Volkmar Müller, Margherita Auer, et al.
Breast Cancer Research : BCR|February 14, 2015
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studiesMichael J Duffy, Patricia M McGowan, Nadia Harbeck, et al.
Anti-Cancer Drugs|December 13, 2006
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrierHans-Joachim Stemmler, Manfred Schmitt, Amina Willems, et al.
Cancer|May 10, 2022
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancerNadia Harbeck, Harold J Burstein, Sara A Hurvitz, et al.
Cancer Nursing|September 28, 2011
Associations between hospital and patient characteristics and breast cancer patients' satisfaction with nursing staffChristoph Kowalski, Sophie E Diener, Petra Steffen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 20, 2004
Biomolecular features of clinical relevance in breast cancerMaria Grazia Daidone, Angelo Paradiso, Massimo Gion, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Use of the Gene Expression Test Prosigna<sup>®</sup> in Premenopausal Patients with HR+, HER2- Early Breast Cancer: Correlation of the Results with the Proliferation Marker Ki-67Cordula Ziegler, Karl Sotlar, Daniel Maria Hofmann, et al.
Pageof 59